Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
about
Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activitiesValidation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates.Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders.Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanilCytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.Fexofenadine hydrochloride in the treatment of allergic disease: a reviewSimultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometryEvaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using felodipine and hesperetin in combination in Wistar rats and everted rat gut sacs in vitro.Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro.Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites.
P2860
Q28269209-218BCCAB-F32E-4D2E-9859-08608DF343A5Q33639593-09022D7F-A5E3-4E16-B5CC-0B0D2C8DD231Q34604652-2C544100-0BB2-4B89-AD7C-E247BA475A0AQ34988193-3DABC78B-6CCC-4F85-83FD-4F8B7FB63C07Q36637864-A1144BD1-971B-4F5F-AC81-46DD302979F5Q36641870-3C862E46-FBFE-4B06-817E-253D8D105CC2Q36646017-6955095B-AE11-448E-A5E9-35003A30855FQ37325606-2B4FAEA7-8906-463F-B9C2-BA1220882F09Q37857671-0782F762-A781-41D0-9A05-ED6A230E3185Q41985982-6417FC59-147F-44A1-AE08-0F2F0C5E69D4Q44666069-6595F678-2DDD-4B46-8A78-00E2AFD4B59EQ46711328-C28BD894-38AF-47CB-B699-10EDFA0ADFF3Q46780885-577295D4-E91D-48B0-87A3-F817CB250245Q50924422-1D718E1A-58EB-495E-AE70-375BCF11CEF1
P2860
Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Evaluation of first-pass cytoc ...... d fexofenadine in combination.
@en
Evaluation of first-pass cytochrome P4503A
@nl
type
label
Evaluation of first-pass cytoc ...... d fexofenadine in combination.
@en
Evaluation of first-pass cytochrome P4503A
@nl
prefLabel
Evaluation of first-pass cytoc ...... d fexofenadine in combination.
@en
Evaluation of first-pass cytochrome P4503A
@nl
P2093
P2860
P356
P1476
Evaluation of first-pass cytoc ...... d fexofenadine in combination.
@en
P2093
Alysa Walker
Christine Hoffer
Evan D Kharasch
Pamela Sheffels
P2860
P356
10.1177/0091270004269705
P577
2005-01-01T00:00:00Z